Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vincristine liposomal - Spectrum Pharmaceuticals

Drug Profile

Vincristine liposomal - Spectrum Pharmaceuticals

Alternative Names: Marqibo; Sphingosomal vincristine; Vincacine; Vincristine sulfate injection; Vincristine sulfate liposomes injection; VSLI

Latest Information Update: 22 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inex Pharmaceuticals Corporation
  • Developer CASI Pharmaceuticals; Hana Biosciences; Inex Pharmaceuticals Corporation; Spectrum Pharmaceuticals; Talon Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Vinca alkaloids
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase III Non-Hodgkin's lymphoma
  • Phase I/II Cancer
  • Preclinical Multiple myeloma
  • Discontinued Colorectal cancer; Malignant melanoma; Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 17 Jan 2019 Spectrum Pharmaceuticals and Acrotech Biopharma enters into a definitive agreement to sell Vincristine liposomal
  • 14 Aug 2018 CASI Pharmaceuticals expects that the CFDA will complete the review of Marqibo’s import drug clinical trial application within the next four to six months
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top